CSG Cloud-Native Rating and Charging Solution Now in Production With Customers Worldwide
29.4.2020 15:00:00 EEST | Business Wire | Press release
CSG ® (NASDAQ: CSGS) today introduced a new addition to its Ascendon platform, CSG Ascendon Rating & Charging, a fully cloud-native, serverless charging software as a service (SaaS). Now actively in use, the solution provides CSG customers with real-time online charging functionality and rating capabilities to support and scale for wireless and digital services offered today and in the future.
As device types and connections surge, operators need highly flexible solutions to rate and charge for events in real-time, at scale, and for innovative monetization models. As a fully hosted, multi-tenant, SaaS solution architected on Amazon Web Services (AWS), Ascendon Rating and Charging elastically scales when volumes fluctuate allowing for efficient and cost-effective management of network resources.
The solution can be used to configure any combination of products, offers, and eligibility rules, as well as how they are sold across channels, in a matter of minutes. It enables balance sharing across multiple devices and services and gives operators the ability to charge dynamically based on network events, with real-time notifications to help engage the customer.
The solution also provides online charging system (OCS) capabilities including real-time authorization and balance management for voice, data, content and digital services; usage processing and rating; and dynamic entitlements that ensure accurate charging.
“Modern business models are centered around emerging digital offers that can be deployed quickly and cost effectively,” said Chad Dunavant, head of global product management, CSG. “CSG Ascendon Rating and Charging is a new breed of cloud-native SaaS that helps operators successfully deploy new services like 5G, while helping them manage risk and optimize operational costs.” (video)
Key technical features include:
- Resiliency by design: High availability and geographically distributed across multiple AWS availability zones (AZs) to help ensure a fail-proof environment. It exceeds the resilience of traditional data centers by utilizing multiple AZs by design, providing a minimum of active-active-active configuration.
- Grow as you go: Provides an unlimited supply of cloud-compute and scalability through AWS, taking the guesswork out of required capacity and eliminating the need for large upfront capital expenditures, lowering operational costs.
- Fully featured and highly flexible: Configurable to support any wireless or digital service or bundled offer, as well as multiple charging models including pre-pay, post-pay, currency conversion, payments, invoicing, and adjustments.
- Fully managed: Complete management of operations and issues, as well as automated quarterly releases deployed by CSG, allowing for rapid deployment of new features and efficient management of resources internally.
- Network/platform agnostic: Charge for any transaction across any network or service platform.
This solution is part of CSG Ascendon, a globally recognized and award-winning digital monetization platform that has helped some of the world’s most innovative companies not just compete but thrive in the digital economy. Ascendon is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities that support more than 500 companies globally, providing them with flexible and configurable technology solutions that help them monetize and digitally enable their customer experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005067/en/
Contact information
Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com
David Banks
Investor Relations
CSG
+1 (303) 200-3127
david.banks@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom